Survival rates improving for many Americans with a variety of cancers
the ONA take:
According to a new report published in the journal JAMA Oncology, researchers from the Cancer Epidemiology Research Program at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, have found that survival rates are improving for many people with breast, colon, liver, lung, and prostate cancer.
Survival rates are particularly improving for those diagnosed at younger ages. The researchers also observed differences in survival based on race.
Specifically, blacks had poorer survival compared with whites. Of note, results showed black women with ovarian cancer experienced an increase in risk of death over the last 20 years.
In addition, many patients aged 50 to 64 with breast, colorectal, liver, or prostate cancer had significantly increased odds of survival, but patients aged 75 to 85 with the same cancers had smaller decreases in risk of death.
For the study, researchers analyzed data on over 1 million patients diagnosed with breast, colorectal, liver, lung, ovarian, pancreatic, or prostate cancer between 1990 and 2009 from the U.S. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) study.
A cancer false alarm may give false sense of security
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|